- The biggest thing affecting our future is third-party validation. A successful trial, and investor follow-through after seeing the apceth deal and our academic research partnerships, will prove our technology is a profit-driver.
- We have plenty of cash, though, so we are not likely to issue more shares.
- The partnership deals bring upfront and early milestone payments that will generate more cash.
- we control the most revolutionary manufacturing technology for the foreseeable future. The endgame is to get that technology into the hands of big pharma and big biotech. When Johnson & Johnson moves into stem cells, its executives do not want to see a line of bone marrow donors cued outside the MSC factory
- We do not expect to be acquired before we grow our share price on the back of some initial partnering deals, but there will be a premium attached when we are bought out.
- We have an ~AU$25M market cap. By comparison, Mesoblast has an ~AU$542M market cap. There is a ton of upside for investors.
CYP Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)